Premium
BENDAMUSTINE (B), FOLLOWED BY OBINUTUZUMAB (G) AND VENETOCLAX (A) IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): CLL2‐BAG TRIAL OF THE GERMAN CLL STUDY GROUP (GCLLSG)
Author(s) -
Cramer P.,
Tresckow J.,
Bahlo J.,
Robrecht S.,
AlSawaf O.,
Langerbeins P.,
Engelke A.,
Fink A.M.,
Fischer K.,
Seiler T.,
Weikersthal L.Fischer,
Hebart H.,
Kreuzer K.A.,
Ritgen M.,
Kneba M.,
Wendtner C.M.,
Stilgenbauer S.,
Eichhorst B.,
Hallek M.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2437_5
Subject(s) - bendamustine , medicine , obinutuzumab , venetoclax , debulking , clinical endpoint , surgery , neutropenia , population , oncology , minimal residual disease , gastroenterology , chronic lymphocytic leukemia , clinical trial , chemotherapy , leukemia , cancer , environmental health , ovarian cancer